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This study analyzed potential drug interactions (PDIs) of antimicrobials used in patients 
of hematopoietic stem cell transplantation and identified associated factors. The sample 
consisted of 70 patients admitted to a hospital in São Paulo. The PDIs were analyzed through 
the consultation of the Drug Interactions Facts and Drug Interactions Handbook. Descriptive 
statistics and logistic regression were used. Half of the sample was exposed to 13 PDIs, 
which occurred with fluconazole (53.8%), ciprofloxacin (30.8%) and sulfamethoxazole-
trimethoprim (15.4%). Most (92.3%) were of moderate severity, with good evidence 
(61.6%), early delayed effect (61.5%) and need to have their therapy monitored (76.9%). 
Patients with four or more medications (p<0.001), aged between 40-49 years of age (p 
<0.001), and being male (p<0.001) were associated with PDIs. A PDI may result in adverse 
outcomes, impacting patients’ morbidity and mortality. Combination regimens can be safe, 
provided there is careful monitoring by professionals involved in care delivery.
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Interações medicamentosas de antimicrobianos utilizados em 
transplante de células-tronco hematopoéticas
Neste estudo, analisaram-se as interações medicamentosas potenciais (IMP) de 
antimicrobianos, usados em pacientes submetidos a transplante de células-tronco 
hematopoiéticas e foram identificdos os fatores associados às IMPs. A casuística foi 
composta por 70 pacientes internados em hospital do município de São Paulo. As IMPs 
foram analisadas através da consulta ao Drug Interactions Facts e Drug Interactions 
Handbook. Na análise dos dados, utilizou-se estatística descritiva e regressão logística. 
Metade da amostra foi exposta a 13 IMPs, que ocorreram com fluconazol (53,8%), 
ciprofloxacina (30,8%) e sulfametoxazol+trimetoprima (15,4%). A maioria (92,3%) 
apresentou gravidade moderada, início de efeito demorado (61,5%) e necessidade 
de monitorar a terapia (76,9%). Quatro ou mais medicamentos (p<0,001), idade 40-
49 anos (p<0,001), sexo masculino (p<0,001) foram associados ao risco de IMP. As 
implicações das IMPs podem resultar em desfechos adversos, causando impacto na 
morbimortalidade do paciente. Os regimes combinados podem ser seguros, desde que 
haja monitoramento criterioso por parte dos profissionais envolvidos no cuidado.
Descritores: Interações de Medicamentos; Enfermagem Oncológica; Avaliação em 
Enfermagem.
Interacciones medicamentosas de antimicrobianos utilizados en 
trasplante de células madre hematopoyéticas
El estudio analizó interacciones medicamentosas potenciales (IMP) de antimicrobianos 
usados en pacientes sometidos a trasplante de células madre hematopoyéticas e identificó 
los factores asociados las IMP. La casuística fue compuesta por 70 pacientes internados en 
un Hospital de Sao Paulo. Las IMP fueron a través de la consulta al Drug Interactions Facts 
y Drug Interactions Handbook. En el análisis de los datos se utilizó estadística descriptiva 
y regresión logística. Mitad de la muestra fue expuesta a 13 IMP, que ocurrieron con 
fluconazol (53,8%), ciprofloxacina (30,8%) y sulfametoxazol+trimetoprima (15,4%). 
La mayoría (92,3%) presentó gravedad moderada, inicio de efecto demorado (61,5%) 
y necesidad de monitorizar la terapia (76,9%). Cuatro o más medicamentos (p<0,001), 
edad entre 40 y 49 años (p<0,001) y sexo masculino (p<0,001), fueron asociados al 
riesgo de IMP. Las implicaciones de las IMP pueden resultar en resultados adversos, 
causando impacto en la morbimortalidad del paciente. Los regímenes combinados pueden 
ser seguros, desde que exista monitorización cuidadosa por parte de los profesionales 
envueltos en el cuidado.
Descriptores: Interacciones de Drogas; Enfermería Oncológica; Evaluación de 
Enfermería.
Introduction
Drug interactions (DIs) are among the main evitable 
causes of adverse drug events (ADEs); DIs represent 
20% to 30% of these and are clinically relevant in 80% of 
the cases, especially among elderly individuals(1-2). Even 
though ADEs accruing from DIs are underreported, they 
are considered to be a health problem because there 
are interactions that cause treatment failure in patients 
without a clinical modification immediately obvious.
DIs occur when a medication (precipitant) interferes 
in the action of another (object). The first causes 
alterations in the pharmacokinetics or mechanism 
of action of the second. Such an event may result in 
three potential outcomes: to increase or reduce the 
therapeutic or the adverse effect, or present a response 
different from what was originally expected from the 
medication(3-4).
962
www.eerp.usp.br/rlae
Rev. Latino-Am. Enfermagem 2011 July-Aug.;19(4):960-7.
The DI phenomenon in the hematology-oncology 
field is still seldom addressed despite the vulnerability 
of patients cared for in this specialty, particularly those 
undergoing hematopoietic stem cell transplantation 
(HSCT). In this type of therapy, the receptor’s marrow 
aplasia is first performed and then, previously treated 
hematopoietic tissue cells or those from a compatible 
donor, are intravenously infused to reestablish 
hematopoiesis(5). Exposure of patients to complex 
therapeutic regimes consisting of a narrow therapeutic 
index, toxicity in various potentially interactive 
organ and antimicrobial systems, association with 
pharmacokinetics and pharmacodynamic variability, 
are some of the factors that increase the risk of DI in 
individuals undergoing HSCT(6-7).
A study conducted with outpatients with solid 
tumors found that 27% of them presented at least one 
DI, which reached 31% of patients treated in a hospice 
care service(8-9). In HSCT patients treated with antifungal 
medication, 86% were exposed to at least one DI and 
26% presented one or more ADE related to the identified 
DI(7). A Brazilian study conducted in a hematology unit 
showed that 95.5% of the sample was exposed to an 
association of potentially interactive medications in the 
post-chemotherapy phase(10). In a general hospital, 63% 
of the hematological patients with solid tumors presented 
at least one DI during hospitalization(11). Even though a 
causal relationship is difficult to establish, the impact of 
DI can be very relevant. One study indicated that 4% 
of deaths identified in hospitalized individuals diagnosed 
with cancer were related to severe DIs(12).
A review paper addressing DIs in organ 
transplantation patients, including bone marrow 
transplantation, reported that antimicrobial medication 
such as fluconazole, trimethoprim/sulphamethoxazole, 
acyclovir, and imipenem interact with cyclosporine, 
one of the most frequently used immunosuppressant 
medications in HSCT(13).
This study was conceived considering that 
antimicrobial medication represent, within the scope of 
HSCT, an essential therapeutic class for the procedure’s 
success, that many of these are introduced in the 
conditioning phase to prevent infections, especially those 
of a fungal nature, and that knowledge of oncologic 
nurses concerning the impact of DIs, even if potential 
knowledge, can help in the monitoring of clinical 
manifestations indicative of DIs. The objectives were 
to analyze the potential antimicrobial medication DIs 
in the case of HSCT patients concerning the following 
aspects: severity, scientific evidence, potential clinical 
implications, effect onset time, and risk level of mixed 
therapy, in addition to identifying factors associated with 
interactions.
Methods
This cross-sectional and prospective study was 
conducted in the HSCT ward in the Instituto de Coração 
[Heart Institute] at the Hospital das Clinicas, University 
of São Paulo, Medical School. The sample was composed 
of 70 patients in the conditioning phase on the day 
prior to bone marrow infusion (day 1), regardless of 
race, diagnosis, age or gender, hospitalized between 
January and July 2005. Given the fact that the focus of 
this investigation was antimicrobial medication, which 
was included in the therapeutic scheme for infection 
prophylaxis on day 1 according to the facility’s protocol 
and the needs of each patient, we opted for analyzing 
the therapy medication on this specific day. Patients 
referred to the intensive therapy unit or those who died 
on the day of study were excluded.
Data collection proceeded after the project was 
approved by the Research Ethics Committee (Protocol 
Nº1107/04) at the hospital and was carried out in two 
phases. The first phase included consulting patients’ 
medical files to obtain information about the patients and 
medications prescribed, from which the following variables 
were collected: age, gender, diagnosis, HSCT type, type 
of central catheter, the medication’s name, route of 
administration and time. In the second phase, specific 
literature was examined to classify DIs, whose variables 
included: severity, scientific evidence, potential clinical 
implications, effect onset time, and risk of mixed therapy.
In this study the term ‘Potential Drug Interaction’ 
(PDI) was used, which refers to the chance of a given 
medication altering the intensity of the pharmacological 
effect of another medication included in the therapy.
PDIs were classified based on studies of renowned 
authors(3-4). The effects accruing from DIs in the severity 
degree classified as ‘Major’ threaten one’s life and may 
cause permanent damage. In ‘Moderate’ severity, responses 
may harm patients or increase their time of hospitalization, 
while effects in ‘Minor’ severity are mild and consequences 
may either bother the individual or even pass unnoticed, 
though additional therapy is required(3).
Five categories were considered to constitution 
scientific evidence: Established, Likely, Suspected, 
Possible and Unlikely. Documentation in the category 
‘established’ is included when there is evidence through 
the occurrence of DI in well-controlled studies. DI is 
considered ‘likely’ when it is typical though not clinically 
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proved; ‘suspected’ if DI can occur, if there is some 
information related to the event though further studies 
are required. ‘Possible’ when DI may occur but data are 
very limited, and ‘unlikely’ when there is no evidence 
of alteration of clinical effects in patients(3). Effect onset 
time refers to the point when an adverse effect appears 
and DIs are classified as ‘fast’ (within 24 hours) and 
‘delayed’ (days or weeks)(3).
The risk of mixed therapy was classified into five 
levels: A – there is no known occurrence of DI; B – 
no therapeutic action is required; C – Monitor therapy; 
D – Consider changing therapy; and X – Avoid mixed 
therapy with analyzed agents(4).
The Statistical Package for the Social Sciences 
(SPSS) program version 13.0 was used in data analysis. 
Multivariate logistic regression adjusted by gender and 
age was used to verify any association between the 
independent variables (gender, age, HSCT type and 
number of administered medication) and the dependent 
variable (PDI). The level of significance was fixed at 
p<0.05.
Results
Most (97.2%) of the sample was composed 
of individuals affected by malignant hematological 
diseases, submitted to autologous HSCT (65.7%) and 
received medication through semi-implanted venous 
catheters (94.3%), as shown in Table 1. The median 
Variables 
Patients (n=70)
n %
Gender
Male 37 52.9
Female 33 47.1
Diagnosis
Lymphomas (HL/NHL) 27 38.6
Leukemia ( AML/CML/ALL 21 30.0
Multiple Myeloma 17 24.3
Myelodysplastic syndrome 3 4.3
Aplastic anemia 1 1.4
Testicular cancer 1 1.4
Type of transplant
Autologous 46 65.7
Allogeneic 24 34.3
Type of catheter
Hickman 42 60.0
Permcath 24 34.3
Port-a-cath 4 5.7
Table 1 – Distribution of sample according to gender, 
diagnosis, and type of transplantation. São Paulo, SP, 
Brazil 2005
HL – Hodgkin’s Lymphoma; NHL- Non-Hodgkin lymphoma, AML- Acute 
Myeloid Leukemia, CML- Chronic Myeloid Leukemia, ALL- Acute Lymphocytic 
Leukemia
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The median of administered medication in 24h was 
eight medications (varied from 4 to 16) while 53.9% of 
the sample received eight or more agents (Figure 1).
age of patients was 36 years old (variation from 10 to 
50 years old).
Figure 1 – Percentage of patients according to medication used in 24-hour period. São Paulo, SP, Brazil 2005
A total of 33 different drugs were identified in 
therapy, 27.3% of which were anti-microbial drugs. 
This class utilized by the sample included: acyclovir 
(70;100%), cefepime (33;47.1%), fluconazole 
(32;45.7%), teicoplanin (7;10%), ciprofloxacin 
(1;1.4%), levofloxacin (7;10%), meropenem (3;4.3%), 
sulfamethoxazole+trimethoprim (9;12.9%) and 
vancomycin (1;1.4%). Among these, 75% (n=6) 
presented potentially interactive characteristics, 
which were examined in light of PDI. Hence, the 
analysis included fluconazole and ciprofloxacin and 
sulfamethoxazole+trimethoprim. Levofloxacin, 
vancomycin and teicoplanin did not present combinations 
that resulted in PDI.
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Considering the total number of used medications 
(n=33), 32 distinct PDIs were identified, while 71.4% 
(n=50) of the sample presented at least one PDI. In 
the PDI analysis of anti-microbial medication, half 
of the patients (n=35) were exposed to 13 PDIs. 
Of these, 53.8% occurred with fluconazole, 30.8% 
with ciprofloxacin and 15.4% due to the use of 
sulfamethoxazole+trimethoprim.
Among the patients using fluconazole (n=32) 93.7% 
presented at least one PDI. Two PDIs were identified 
with the use of sulfamethoxazole+trimethoprim, which 
occurred in four different patients while four PDIs were 
observed in a single patient with the use of ciprofloxacin.
PDIs of anti-microbial medication were of a 
pharmacokinetic nature, 84.6% capable of modifying 
the pattern of metabolism, interfering in serum levels of 
the object-medication.
Most PDIs (92.3%) presented moderate severity 
with scientific evidence originating from non-controlled 
studies (53.8%), which could result in increased serum 
levels of the object-medication (77.0%), with delayed 
effect time onset (61.5%); the risk of mixed therapy 
involved implies the need to monitor serum levels and 
the toxicity of the agents involved (76.9%) (Table 2).
Logistic regression indicated that being a man 
(OR=2.4), between 40 and 49 years of age (OR=6.1), and 
using four or more medications (OR=6.9) significantly 
increased the risk of PDI (Table 3).
Table 2 – Description of potential drug interactions of anti-microbial medication. São Paulo, SP, Brazil 2005
* Drug Interaction Facts(3); † Drug Interaction Handbook(4); NS – not specified;     = Increase     = Decrease
Table 3 – Association among potential drug interactions 
and clinical-demographic variables. São Paulo, SP, Brazil 
2005
Variables Odds Ratio * (CI – 95%) p
Gender
Female 1.00
Male 2.412 (2.013 – 2.887) < 0.001
Age
≤ 19 1.00
20 – 29 0.977 (0.634 – 1.506) 0.917
30 – 39 1.541 (0.993 – 2 .392) 0.054
40 – 49 6.176 (4.008 – 9.516) < 0.001
≥ 50 1.616 (1.096 – 2.382) 0.015
Type of transplant
Autologous 1.00
Allogenic 0.826 (0.664 - 1.028) 0.087
Number of drugs
< 4 1.00
≥ 4 6.951 (5. 561- 8.687) < 0.001
*Adjusted by gender and age. CI = Confidence Interval
Discussion
Patients undergoing HSCT were particularly 
susceptible to PDIs, not only due to their clinical 
particularities but also due to their pharmacological 
therapy profiles composed of various medications, 
many with potentially interactive characteristics, which 
were implicated in many important DIs. As indicated 
in previous studies, they could harm patients (7,14). 
However, it is possible that the effects accruing from 
PDIs pass unnoticed in these patients or are interpreted 
as manifestations of a disease’s clinical development 
because of their condition’s complexity.
The relationship between the number of medications 
and DIs was well documented in the literature by various 
authors(8-9,11,14-15). This study revealed that the chances of a 
PDI occurring was almost seven times greater (OR-=6.9) 
when the patient used four or more medications. A recent 
Potential Drug Interaction
Cases (n=70)
Severity * Scientific evidence * Clinical Implication * Onset *
Risk of combined 
therapy †  n %
Fluconazole+omeprazole 28 40.0 Moderate Suspected  absorption of antifungal medications Fast D
Fluconazole+diazepam 13 18.5 Moderate Established     Diazepam serum levels Fast C
Fluconazole+cyclosporine 11 15.7 Moderate Established     cyclosporine serum levels Delayed C
Fluconazole+dexamethasone 10 14.2 Moderate Suspected     corticosteroid serum levels Delayed C
Fluconazole+phenytoin 3 4.2 Moderate Likely     phenytoin serum levels Delayed D
Fluconazole+sertraline 2 2.8 Moderate NS     sertraline serum levels NS C
Sulfamethoxazole + trimethoprim 
+ cyclosporine 2 2.8 Moderate Suspected     cyclosporine serum levels Delayed C
Sulfamethoxazole+trimethoprim+
phenytoin 2 2.8 Moderate Likely     phenytoin serum levels Delayed C
Ciprofloxacin + cyclophosphamide 1 1.4 Moderate Possible     antimicrobial effect Delayed C
Ciprofloxacin + cyclosporine 1 1.4 Moderate Suspected     cyclosporine serum levels Delayed C
Ciprofloxacin + dexamethasone 1 1.4 Moderate NS     excretion of both NE C
Ciprofloxacin +diazepam 1 1.4 Minor Possible     diazepam serum levels Delayed C
Fluconazole+ cyclophosphamide 1 1.4 Moderate NS     cyclophosphamide serum levels NE C
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study conducted in an intensive therapy unit reported a 
positive association between the number of medications 
and potential interactions on the patient’s sixth day of 
hospitalization(15). Oncologic studies addressing different 
contexts concluded that the number of medications was 
also a predictive factor for DIs(8-9,11). Regardless of the 
investigation’s context, these authors analyzed clinically 
chronic(8-9,11) and severely acute(15) patients. Hence, the 
complexity of the therapy is closely related to the risk of 
PDIs, whether these are mild or severe.
Being between 40 to 49 years old was also a factor 
associated with PDIs. However, being within the older ages 
in the different age ranges (30-39 years old, OR=1.54 
and 50 years old or older, OR=1.61) was an indicator of 
risk for PDIs, even though for those between 30 and 39 
years old no statistically significant difference (p=0.054) 
was found for the level of significance at 5%. It is possible 
that this result being close to the rejection limit is due to 
the sample size. Even though these individuals were not 
included in the most vulnerable group, it is known that 
renal structural changes occur with aging and these can 
have an impact on the excretion of medication, increasing 
toxicity of co-administered medications and chances of 
PDI. It is estimated that weight and renal volume reduce 
from 20% to 30% between 30 and 90 years of age, the 
number of glomeruli is reduced 30% to 50% and renal 
plasma flow reduces more than 600ml/min at 30 years of 
age and up to 300m/min at 80 years of age(16).
There was no statistically significant association 
in relation to the type of HSCT. Although empirical 
observation has shown that allogeneic HSCT seems to 
have a greater tendency to develop PDIs given the use 
of cyclosporine. It was the only medication involved 
in all PDIs with anti-microbial medications, which is 
mandatory in this kind of transplantation and used in all 
the studied patients.
Fluconazole was the agent most frequently 
involved in PDIs, certainly due to two aspects: it was 
the anti-microbial medication most prescribed in the 
studied sample (45.7%) and is an enzymatic inhibitor of 
the cytochrome system P450 (CYP450) of isoenzymes 
CYP2C8/9, CYP2C19 and CYP3A4 responsible for 
metabolizing various medications used in HSCT(3-4,7,10).
Most of the PDIs could increase the serum levels of 
the object medication, especially cyclosporine, since this 
immunosuppressive drug was involved in PDIs with three 
antimicrobial medications. Even though the object agent 
is the same in each PDI, the clinical implication depends 
on the effect caused by precipitants (fluconazole, 
ciprofloxacin, and sulfamethoxazole+trimethoprim).
Cyclosporine is a substrate of the isoenzyme 
CYP3A4 and its co-administration with fluconazole tends 
to increase the pharmacological effects and toxicity 
of the immunosuppressant drug evidenced through 
nephrotoxicity, cholestasis or paresthesias(3-4). Hence, 
even though toxicity was not assessed, almost half of 
the patients undergoing allogeneic HSCT (n=24) were 
exposed to this PDI. In a previous study, this DI was also 
identified in patients treated with antifungal drugs(17).
Sulfamethoxazole+trimethoprim was prescribed to 
HSCT patients at the beginning of the conditioning phase 
as prophylaxis for Pneumocistis carinii and the therapy 
was interrupted on day 1. However, cyclosporine was 
introduced on day 1, a situation that certainly predisposes 
one to PDIs, and may increase nephrotoxicity and the risk 
of graft rejection(3-4,13). The enzymatic inhibition process 
triggered by sulfamethoxazole+trimethoprim is slow 
and even if it is suspended on day 1, the effects accruing 
from the PDI should be carefully monitored, especially 
on those patients with nephrotoxicity(3-4,7,13,18)..
In relation to the PDI ciprofloxacin+cyclosporine, 
a case report of a patient with bone marrow aplasia 
showed that the mixed therapy resulted in increased 
immunosuppressive serum levels, though with no 
severe consequences occurred due to the timeliness in 
adjusting the drug dosage(19).
The onset time of interactions was delayed in 
most cases (61.5%), which is an additional reason to 
monitor patients during the entire follow-up period 
(at hospitals and outpatient clinics). Even though 
some medications used at the beginning of medullar 
conditioning are suspended for the introduction of 
others, the pharmacological mechanisms that involve 
PDIs are delayed, and can take from days to weeks, 
so that the signs and symptoms may remain hidden 
in the pre HSCT phase, though subject to appear post 
operative. Such a fact may put at risk the success of the 
therapy if we consider that the number of medications 
used in neutropenia (post HSCT) is even larger, which 
increases the risk of PDIs. This is especially so when 
enzymatic inhibitors are used.
Even though more than half of PDIs were noted based 
on scientific evidence that came from non-controlled 
studies, these originated from information bases respected 
in the scientific milieu. The Drug Interaction Facts(3) was 
considered to be highly accurate when compared to other 
PDI screening sources, with a sensitivity of specificity of 
97%(20). Also the author of this compendium is one of the 
main information sources concerning DIs, hence it is used 
in various studies(8-9,11,14).
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In relation to the risk of mixed therapies, 
we verified that, with the exception of two PDIs, 
fluconazole+omeprazole and fluconazole+phenytoin, the 
remaining were classified as C, that is, a recommendation 
to monitor the therapy. From a practical point of view, 
the activity “monitor therapy” should to be shared among 
different professionals, e.g. physicians, pharmacists and 
nurses. The latter should know the clinical manifestations 
that accrue from PDIs so they can guide the nursing 
staff in how to search for warning signs, especially in 
the field of oncology, in which patients are frequently 
exposed to complex therapeutic regimes. Additionally, it 
is essential that measures aimed to reduce the risk and 
management of PDIs are implemented, including: the 
use of DI tables in the hospitalization units; electronic 
prescriptions with DI alerts; dosage adjustments based 
on serum levels, especially of object-medication; 
schedules based on the pharmacokinetics characteristics 
of the combined medications on the part of the nursing 
staff; and change therapy when the classification of the 
risk of therapy is either D or X(4).
This study was a pioneer in the investigation of this 
theme in the context of oncologic nursing, in addition 
to bringing information concerning PDIs, the level of 
risk in the case of mixed therapies, variables that can 
support clinical practice by indicating actions to be 
implemented by professionals, especially in relation to 
the inclusion of specific items in nursing prescription. 
PDIs were identified based on Drug Interaction Facts, 
a reference used in various studies, which enables 
comparisons with future investigations. However, there 
are limitations that deserve to be noted so they can be 
appropriately handled in future studies. Even though the 
sample was limited to a single facility, the therapeutic 
protocols reflect the current practice of therapy. Data 
were collected on day 1 and excluded the possibility of 
identifying other PDIs, since once a patient is in the post 
HSCT phase, the regimen becomes even more complex. 
The PDI analysis included only the potentially interactive 
anti-microbial medications, an aspect that certainly led 
to an underestimated occurrence of PDIs. Finally, the 
PDI outcomes were not evaluated, but only the risk of 
patients to be exposed to a PDI.
Conclusion
PDIs involving the anti-microbial drugs fluconazole, 
ciprofloxacin and sulfamethoxazole+trimethoprim 
predominantly presented moderate severity. Even then 
alterations of medications’ serum levels are indicated 
due to potential clinical implications, especially for 
cyclosporine, which can lead to adverse outcomes such as 
graft rejection (reduced serum levels) and nephrotoxicity 
(increased serum levels). These are delayed effects but 
they can have an impact on the morbidity and mortality 
of patients undergoing HSTC. Evidence concerning PDIs 
originate from non-controlled studies that do not refer to 
essential clinical studies or controlled studies that could 
corroborate or refute data obtained from case reports. 
However, the combined therapy utilizing anti-microbial 
drugs and object-medication such as cyclosporine, 
essential in allogeneic HSCT, can be safe if professionals 
share responsibility in relation to the control of serum 
levels of such agents. Among other factors, responsibility 
may include a possible dosage adjustment and rigorous 
monitoring of effects that accrue from PDIs, especially 
for individuals in risk groups, such as being older than 
30 years of age and using four or more medication.
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